Science News

Role of the 12-Lipoxygenase Pathway in Diabetes Pathogenesis and Complications.

A new interesting article has been published in Pharmacol Ther. 2018 Oct 19. pii: S0163-7258(18)30194-3. doi: 10.1016/j.pharmthera.2018.10.010. [Epub ahead of print] Review and titled:

Role of the 12-Lipoxygenase Pathway in Diabetes Pathogenesis and Complications.

Authors of this article are:

Dobrian AD, Morris MA, Taylor-Fishwick DA, Holman TR, Imai Y, Mirmira RG, Nadler JL.

A summary of the article is shown below:

12-lipoxygenase (12-LOX) is one of several enzyme isoforms responsible for the metabolism of arachidonic acid and other poly-unsaturated fatty acids to both pro- and anti-inflammatory lipid mediators. Mounting evidence has shown that 12-LOX plays a critical role in the modulation of inflammation at multiple checkpoints during diabetes development. Due to this, interventions to limit pro-inflammatory 12-LOX metabolites either by isoform-specific 12-LOX inhibition, or by providing specific fatty acid substrates via dietary intervention, has the potential to significantly and positively impact health outcomes of patients living with both type 1 and type 2 diabetes. To date, the development of truly specific and efficacious inhibitors has been hampered by homology of LOX family members; however, improvements in high throughput screening have improved the inhibitor landscape. Here, we describe the function and role of human 12-LOX, and mouse 12-LOX and 12/15-LOX, in the development of diabetes and diabetes-related complications, and describe promise in the development of strategies to limit pro-inflammatory metabolites, primarily via new small molecule 12-LOX inhibitors.

Check out the article’s website on Pubmed for more information:



This article is a good source of information and a good way to become familiar with topics such as:

Inflammation;Lipoxygenase;Lipoxygenase inhibitors;Type 1 diabetes;Type 2 diabetes-related complications

.

Categories: Science News